StockNews.com Upgrades MediWound (NASDAQ:MDWD) to Sell

MediWound (NASDAQ:MDWD) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research note issued on Monday.

Several other research analysts have also weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 target price on shares of MediWound in a research report on Tuesday, July 16th. Maxim Group increased their target price on MediWound from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th.

MediWound Price Performance

NASDAQ MDWD traded down $1.13 on Monday, hitting $16.35. 149,637 shares of the company’s stock were exchanged, compared to its average volume of 110,366. The firm has a market cap of $151.73 million, a price-to-earnings ratio of -11.85 and a beta of 0.81. The firm’s 50-day moving average price is $17.26 and its two-hundred day moving average price is $16.00. MediWound has a fifty-two week low of $7.10 and a fifty-two week high of $24.00.

MediWound (NASDAQ:MDWD) last announced its earnings results on Wednesday, May 29th. The biopharmaceutical company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. MediWound had a negative return on equity of 21.67% and a negative net margin of 64.24%. The firm had revenue of $4.96 million for the quarter, compared to analysts’ expectations of $4.65 million. On average, research analysts predict that MediWound will post -1.86 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Janney Montgomery Scott LLC acquired a new stake in shares of MediWound during the first quarter valued at about $427,000. Yelin Lapidot Holdings Management Ltd. grew its stake in shares of MediWound by 45.7% during the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 125,493 shares of the biopharmaceutical company’s stock valued at $1,276,000 after acquiring an additional 39,348 shares in the last quarter. Sargent Investment Group LLC grew its stake in shares of MediWound by 7.0% during the fourth quarter. Sargent Investment Group LLC now owns 109,194 shares of the biopharmaceutical company’s stock valued at $1,111,000 after acquiring an additional 7,125 shares in the last quarter. Silverberg Bernstein Capital Management LLC grew its stake in MediWound by 7.8% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 85,184 shares of the biopharmaceutical company’s stock worth $1,214,000 after purchasing an additional 6,200 shares in the last quarter. Finally, Rhumbline Advisers acquired a new position in MediWound in the second quarter worth about $131,000. 46.83% of the stock is owned by hedge funds and other institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.